Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Healthcare company Regeneron was a detractor in the quarter after disappointing trial results for one of its pipeline drugs. When we first...
— Southeastern Asset Management, Inc.
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals ($REGN), representing 4.7% of the fund's portfolio, is a leading biotechnology company that discovers, invents, and commercializes innovative medicines for serious diseases. The manager maintains...
Regeneron Pharmaceuticals is a leading biotechnology firm that invents, develops, and commercializes medicines for serious conditions, particularly in immunology and oncology. Regeneron represents 6.5%...
More institutional theses from Longleaf Partners Fund
Mattel is a global toy, entertainment, and consumer products enterprise that owns iconic intellectual property franchises including Barbie, Hot Wheels, and Fisher-Price. Mattel represents 6.4%...
Avantor provides mission-critical products and workflow services to life sciences and advanced technology industries globally, distributing laboratory chemicals, equipment, and bioprocessing consumables. The manager holds...
Fortune Brands Innovations manufactures leading home and building products across security, water, and outdoor living categories. The manager maintains...